The U.S. Food and Drug Administration (FDA) has approved Syndax‘s oral therapy Revuforj (revumenib) as a treatment for certain people with acute myeloid leukemia…
Blood cancer
All three adults with high-risk acute myeloid leukemia (AML) who had already been given 3-4 lines of cancer treatment responded to a combination of Venclexta…
The Advanced Research Projects Agency for Health (ARPA-H) has awarded up to $48 million to Kernal Bio to support the development of more efficient,…
The U.S. Food and Drug Administration has approved a new rapid diagnostic test to identify patients with treatment-resistant acute leukemias who may benefit from the…
A new research project aims to make it easier for people with acute myeloid leukemia (AML) to participate in clinical trials. The project is led…
The National Comprehensive Cancer Network (NCCN), a nonprofit alliance of 33 cancer centers, included Revuforj (revumenib) in its clinical practice guidelines for treatment of relapsed or…
The advocacy organization Blood Cancer United has teamed up with motor oil company Valvoline Global and auto racing group Hendrick Motorsports to raise awareness…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to CER-1236, an experimental cell therapy that Cero Therapeutics is developing to…
Xspray Pharma has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for its oral therapy XS003 (nilotinib) for the…
Biotech company Schrödinger said it’s discontinuing the development of SGR-2921, an experimental therapy for certain types of blood cancer, following the deaths of…
